{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:40Z","timestamp":1793834860798,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early identification of cognitive impairment in Parkinson\u2019s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at amino acid 181 (p-tau181) and plasma neurofilament light chain (NfL) as biomarkers of cognition in PD. Baseline concentrations of plasma p-tau181 and NfL were measured in a cohort of 136 patients with PD and 63 healthy controls (HC). Forty-seven PD patients were followed up for up to 2 years. Cross-sectional and longitudinal associations between baseline plasma biomarkers and cognitive progression were investigated using linear regression and linear mixed effects models. At baseline, plasma p-tau181 concentration was significantly higher in PD subjects compared with HC (<jats:italic>p<\/jats:italic>\u2009=\u20090.026). In PD patients, higher plasma NfL was associated with lower MMSE score at baseline, after adjusting for age, sex and education (<jats:italic>p<\/jats:italic>\u2009=\u20090.027). Baseline plasma NfL also predicted MMSE decline over time in the PD group (<jats:italic>p<\/jats:italic>\u2009=\u20090.020). No significant association between plasma p-tau181 concentration and baseline or longitudinal cognitive performance was found. While the role of p-tau181 as a diagnostic biomarker for PD and its relationship with cognition need further elucidation, plasma NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD.<\/jats:p>","DOI":"10.1038\/s41531-022-00384-x","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T14:03:33Z","timestamp":1668261813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-2803","authenticated-orcid":false,"given":"Lucia","family":"Batzu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-9797","authenticated-orcid":false,"given":"Silvia","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Zinzalias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-216X","authenticated-orcid":false,"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"384_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova, N., Padmakumar, C., Lewis, S. J. G. & Chaudhuri, K. R. Parkinson\u2019s: a syndrome rather than a disease? J. Neural Transm. 124, 907\u2013914 (2017).","journal-title":"J. Neural Transm."},{"issue":"Suppl 1","key":"384_CR2","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","volume":"22","author":"A Sauerbier","year":"2016","unstructured":"Sauerbier, A., Jenner, P., Todorova, A. & Chaudhuri, K. R. Non motor subtypes and Parkinson\u2019s disease. Parkinsonism Relat. Disord. 22(Suppl 1), S41\u2013S46 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"384_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/mds.27027","volume":"32","author":"N Titova","year":"2017","unstructured":"Titova, N. & Chaudhuri, K. R. Personalized medicine in Parkinson\u2019s disease: time to be precise. Mov. Disord. 32, 1147\u20131154 (2017).","journal-title":"Mov. Disord."},{"key":"384_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Prim. 7, 47 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"384_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/mds.23661","volume":"26","author":"C Vossius","year":"2011","unstructured":"Vossius, C., Larsen, J. P., Janvin, C. & Aarsland, D. The economic impact of cognitive impairment in Parkinson\u2019s disease. Mov. Disord. 26, 1541\u20131544 (2011).","journal-title":"Mov. Disord."},{"key":"384_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag, A., Siddiqui, U. F., Anastasiou, Z., Weintraub, D. & Schott, J. M. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol. 16, 66\u201375 (2017).","journal-title":"Lancet Neurol."},{"key":"384_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton, N. J. et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat. Rev. Neurol. 16, 265\u2013284 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"384_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson, D. W. et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150\u20131157 (2009).","journal-title":"Lancet Neurol."},{"key":"384_CR9","first-page":"1234","volume":"90","author":"C Smith","year":"2019","unstructured":"Smith, C. et al. Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies. J. Neurol. Neurosurg. Psychiatry 90, 1234\u20131243 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"384_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","volume":"266","author":"EW Lim","year":"2019","unstructured":"Lim, E. W. et al. Amyloid-beta and Parkinson\u2019s disease. J. Neurol. 266, 2605\u20132619 (2019).","journal-title":"J. Neurol."},{"key":"384_CR11","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillback","year":"2015","unstructured":"Skillback, T. et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain 138, 2716\u20132731 (2015).","journal-title":"Brain"},{"key":"384_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","volume":"75","author":"A Siderowf","year":"2010","unstructured":"Siderowf, A. et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055\u20131061 (2010).","journal-title":"Neurology"},{"key":"384_CR13","doi-asserted-by":"crossref","unstructured":"Johar, I., Mollenhauer, B. & Aarsland, D. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson\u2019s Disease. Int. Rev. Neurobiol. 132, 275\u2013294 (2017).","DOI":"10.1016\/bs.irn.2016.12.001"},{"key":"384_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"CC Yang","year":"2018","unstructured":"Yang, C. C. et al. Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease. J. Alzheimers Dis. 61, 1323\u20131332 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"384_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"384_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"384_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnagi.2018.00123","volume":"10","author":"CH Lin","year":"2018","unstructured":"Lin, C. H. et al. Plasma biomarkers differentiate Parkinson\u2019s disease from atypical Parkinsonism syndromes. Front Aging Neurosci. 10, 123 (2018).","journal-title":"Front Aging Neurosci."},{"key":"384_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez, M. C. et al. Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies. JAMA Neurol. 79, 32\u201337 (2022).","journal-title":"JAMA Neurol."},{"key":"384_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF00293376","volume":"82","author":"H Yamasaki","year":"1991","unstructured":"Yamasaki, H., Itakura, C. & Mizutani, M. Hereditary hypotrophic axonopathy with neurofilament deficiency in a mutant strain of the Japanese quail. Acta Neuropathol. 82, 427\u2013434 (1991).","journal-title":"Acta Neuropathol."},{"key":"384_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.28056","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov. Disord. 35, 1138\u20131144 (2020).","journal-title":"Mov. Disord."},{"key":"384_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson, B. et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 76, 318\u2013325 (2019).","journal-title":"JAMA Neurol."},{"key":"384_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-021-00232-4","volume":"7","author":"C Quadalti","year":"2021","unstructured":"Quadalti, C. et al. Neurofilament light chain and alpha-synuclein RT-QuIC as differential diagnostic biomarkers in Parkinsonisms and related syndromes. NPJ Parkinsons Dis. 7, 93 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"384_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","volume":"72","author":"DC Backstrom","year":"2015","unstructured":"Backstrom, D. C. et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 72, 1175\u20131182 (2015).","journal-title":"JAMA Neurol."},{"key":"384_CR24","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930\u2013937 (2017).","journal-title":"Neurology"},{"key":"384_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"YS Lin","year":"2018","unstructured":"Lin, Y. S., Lee, W. J., Wang, S. J. & Fuh, J. L. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci. Rep. 8, 17368 (2018).","journal-title":"Sci. Rep."},{"key":"384_CR26","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin, C. H. et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93, e1104\u2013e1111 (2019).","journal-title":"Neurology"},{"key":"384_CR27","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt, W. W. et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov. Disord. 36, 2945\u20132950 (2021).","journal-title":"Mov. Disord."},{"key":"384_CR28","first-page":"e12005","volume":"12","author":"K Dhiman","year":"2020","unstructured":"Dhiman, K. et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer\u2019s disease. Alzheimers Dement. 12, e12005 (2020).","journal-title":"Alzheimers Dement."},{"key":"384_CR29","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston, P. S. J. et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89, 2167\u20132175 (2017).","journal-title":"Neurology"},{"key":"384_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"384_CR31","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","volume":"95","author":"D Backstrom","year":"2020","unstructured":"Backstrom, D. et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 95, e827\u2013e838 (2020).","journal-title":"Neurology"},{"key":"384_CR32","doi-asserted-by":"publisher","unstructured":"Chen, J. H., Chan, L., Chung, C. C., Bamodu, O. A. & Hong, C. T. Blood neurofilament light chain in Parkinson\u2019s disease: comparability between Parkinson\u2019s Progression Markers Initiative (PPMI) and Asian cohorts. J. Clin. Med. 10, https:\/\/doi.org\/10.3390\/jcm10215085 (2021).","DOI":"10.3390\/jcm10215085"},{"key":"384_CR33","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback, T. et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83, 1945\u20131953 (2014).","journal-title":"Neurology"},{"key":"384_CR34","first-page":"00151","volume":"S1353-8020","author":"J Pagonabarraga","year":"2022","unstructured":"Pagonabarraga, J. et al. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson\u2019s disease. Parkinsonism Relat. Disord. S1353-8020, 00151\u20131 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"384_CR35","doi-asserted-by":"publisher","unstructured":"Lin, C. H., Chiu, S. I., Chen, T. F., Jang, J. R. & Chiu, M. J. Classifications of neurodegenerative disorders using a multiplex blood biomarkers-based machine learning model. Int. J. Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21186914 (2020).","DOI":"10.3390\/ijms21186914"},{"key":"384_CR36","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"384_CR37","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1021\/acschemneuro.1c00010","volume":"12","author":"MJ Chiu","year":"2021","unstructured":"Chiu, M. J. et al. Synergistic association between plasma Abeta1-42 and p-tau in Alzheimer\u2019s disease but not in parkinson\u2019s disease or frontotemporal dementia. ACS Chem. Neurosci. 12, 1376\u20131383 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"384_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94345-8","volume":"11","author":"MS Baek","year":"2021","unstructured":"Baek, M. S., Lee, M. J., Kim, H. K. & Lyoo, C. H. Temporal trajectory of biofluid markers in Parkinson\u2019s disease. Sci. Rep. 11, 14820 (2021).","journal-title":"Sci. Rep."},{"key":"384_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00702-016-1517-6","volume":"123","author":"R Biundo","year":"2016","unstructured":"Biundo, R. et al. MMSE and MoCA in Parkinson\u2019s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J. Neural Transm. 123, 431\u2013438 (2016).","journal-title":"J. Neural Transm."},{"key":"384_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","volume":"83","author":"CH Adler","year":"2014","unstructured":"Adler, C. H. et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83, 406\u2013412 (2014).","journal-title":"Neurology"},{"key":"384_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"384_CR42","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u2013442 (1967).","journal-title":"Neurology"},{"key":"384_CR43","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19, 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"384_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14737175.2018.1400383","volume":"18","author":"P Martinez-Martin","year":"2018","unstructured":"Martinez-Martin, P. & Chaudhuri, K. R. Comprehensive grading of Parkinson\u2019s disease using motor and non-motor assessments: addressing a key unmet need. Expert Rev. Neurother. 18, 41\u201350 (2018).","journal-title":"Expert Rev. Neurother."},{"key":"384_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"384_CR46","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov. Disord. 22, 1901\u20131911 (2007).","journal-title":"Mov. Disord."},{"key":"384_CR47","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0b013e3181c0d416","volume":"73","author":"P Martinez-Martin","year":"2009","unstructured":"Martinez-Martin, P. et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 73, 1584\u20131591 (2009).","journal-title":"Neurology"},{"key":"384_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13336","volume":"143","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen, D. J. et al. The Non-Motor Symptoms Scale in Parkinson\u2019s disease: validation and use. Acta Neurol. Scand. 143, 3\u201312 (2021).","journal-title":"Acta Neurol. Scand."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00384-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T11:04:47Z","timestamp":1668337487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00384-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00384-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A., K.R.C., and H.Z. declare they do not have any non-financial competing interest but the financial competing interests are: D.A. has received research support and\/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Sanofi, Evonik, Roche Diagnostics and GE Health, and served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly, Cognetivity, Enterin, Acadia, Sygnature and Biogen; K.R.C. is in the advisory board of AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion, Britannia, Acadia, 4D, has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial and reports grants for investigator initiated studies from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial, academic grants from EU, IMI EU, Horizon 2020, Parkinson\u2019s UK, NIHR, PDNMG, Kirby Laing Foundation, NPF, MRC, Wellcome Trust; H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Programme (outside submitted work). A.R., P.Z., C.F., L.L.G., D.T., A.H., A.H., S.R., And L.B report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}